Standalone AUC
0.732 AUC
- EndpointLesion-level prostate cancer detection
- Population247 lesions from 228 prostate MRI cases
- Tested versionQP-Prostate CAD submitted in K242683; build not stated
FDA-cleared profile
Quibim S.L. · MRI · FDA-cleared (510(k))
Authorized purpose: QP-Prostate CAD detects and marks suspected prostate lesions for clinically significant prostate cancer on bi-parametric T2-weighted and diffusion-weighted prostate MRI, returning moderate/high suspicion overlays in DICOM to third-party workstations/PACS for concurrent physician review; patient management must not rely on it alone.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: QP-Prostate CAD detects and marks suspected prostate lesions for clinically significant prostate cancer on bi-parametric T2-weighted and diffusion-weighted prostate MRI, returning moderate/high suspicion overlays in DICOM to third-party workstations/PACS for concurrent physician review; patient management must not rely on it alone.
Evidence takeaway. Evidence from the reviewed source record: Pivotal validation used 228 prostate MRI cases from multiple U.S. centers, with a nine-reader aided/unaided study; standalone lesion-level analysis included 247 lesions.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
0.732 AUC
0.868 AUC
0.019 AUC difference
K242683
Cases included biopsy/pathology or follow-up reference categories and 1.5T/3T systems from GE, Siemens, and Philips.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Bi-parametric prostate MRI consisting of T2-weighted and diffusion-weighted series from patients above 40 years; the FDA dataset includes 1.5T and 3T GE, Siemens, and Philips systems.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-06 · FDA 510(k) K242683: QP-Prostate CAD
Source context, not route validation: The FDA submission describes standard DICOM overlays returned to third-party workstations and PACS; local PACS and fusion-biopsy compatibility require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-06 · FDA 510(k) K242683: QP-Prostate CAD
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Source context, not route validation: Two-color overlay markings around suspected prostate lesions, distinguishing moderate and high suspicion for clinically significant cancer (Gleason score 7 or greater), returned in standard DICOM formats for third-party workstations and PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-06 · FDA 510(k) K242683: QP-Prostate CAD
Unresolved route: Two-color overlay markings around suspected prostate lesions, distinguishing moderate and high suspicion for clinically significant cancer (Gleason score 7 or greater), returned in standard DICOM formats for third-party workstations and PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-06 · FDA 510(k) K242683: QP-Prostate CAD
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Vendor statement; certificates were not read. Applicant name variants ('QUIBIM S.L.', 'Quibim S.L.') are bridged via the identical distinctive name and QP product naming. Exact-release scope is not established.
The exact submission describes moderate/high suspicion lesion overlays returned in DICOM to third-party workstations and PACS.
exact submission · checked 2026-09-06Quibim's official QP-Prostate page describes prostate segmentation, lesion detection, PI-RADS structured reporting, DICOM, PACS, and fusion-biopsy integration; current exact K242683 compatibility and build require confirmation.
product family · checked 2026-09-07Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public amount, range, currency, geography, or contract term was established.
Bounded web search on 2026-10-26 (query: "Quibim QP-Prostate reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Current onboarding, competency, and support commitments were not established.
Local acceptance testing, production monitoring, update control, and drift review were not established.
8 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary, evidenceMetrics, evidenceStudies
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: productFamilyWorkflow, implementationCapabilities
Scope: security
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Siemens Healthcare GmbH
Authorized purpose: Prostate MR AI (VA10A) is a plug-in CADe/CADx aid for radiologists interpreting prostate MRI in adult men aged 40 years or older with suspected prostate cancer and no prior treatment, using PI-RADS-oriented review; it is not the sole basis for diagnosis or management.
ScanMed, LLC
Authorized purpose: Concurrent CADe/CADx reading aid for qualified physicians interpreting prostate MRI in adult males undergoing screening or clinical MRI, including high-risk screening or diagnostic imaging, to identify prostate abnormalities and regions suspicious for cancer and assess their likelihood of malignancy.
JLK Inc.
Authorized purpose: Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.
Avenda Health, Inc.
Authorized purpose: Adjunctive review of MR prostate images and biopsy findings for prostate segmentation, lesion evaluation, quantification, documentation, and pre-planning biopsy or soft-tissue-ablation procedures.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history